Cargando…
Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
BACKGROUND: Risk assessment is relevant to predict postoperative outcomes in patients with gastro‐oesophageal cancer. This cohort study aimed to assess body composition changes during neoadjuvant chemotherapy and investigate their association with postoperative complications. METHODS: Consecutive pa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528528/ https://www.ncbi.nlm.nih.gov/pubmed/32841538 http://dx.doi.org/10.1002/bjs5.50331 |
_version_ | 1783589280543670272 |
---|---|
author | den Boer, R. B. Jones, K. I. Ash, S. van Boxel, G. I. Gillies, R. S. O'Donnell, T. Ruurda, J. P. Sgromo, B. Silva, M. A. Maynard, N. D. |
author_facet | den Boer, R. B. Jones, K. I. Ash, S. van Boxel, G. I. Gillies, R. S. O'Donnell, T. Ruurda, J. P. Sgromo, B. Silva, M. A. Maynard, N. D. |
author_sort | den Boer, R. B. |
collection | PubMed |
description | BACKGROUND: Risk assessment is relevant to predict postoperative outcomes in patients with gastro‐oesophageal cancer. This cohort study aimed to assess body composition changes during neoadjuvant chemotherapy and investigate their association with postoperative complications. METHODS: Consecutive patients with gastro‐oesophageal cancer undergoing neoadjuvant chemotherapy and surgery with curative intent between 2016 and 2019 were identified from a specific database and included in the study. CT images before and after neoadjuvant chemotherapy were used to assess the skeletal muscle index, sarcopenia, and subcutaneous and visceral fat index. RESULTS: In a cohort of 199 patients, the mean skeletal muscle index decreased during neoadjuvant therapy (from 51·187 to 49·19 cm(2)/m(2); P < 0·001) and the rate of sarcopenia increased (from 42·2 to 54·3 per cent; P < 0·001). A skeletal muscle index decrease greater than 5 per cent was not associated with an increased risk of total postoperative complications (odds ratio 0·91, 95 per cent c.i. 0·52 to 1·59; P = 0·736) or severe complications (odds ratio 0·66, 0·29 to 1·53; P = 0·329). CONCLUSION: Skeletal muscle index decreased during neoadjuvant therapy but was not associated with postoperative complications. |
format | Online Article Text |
id | pubmed-7528528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-75285282020-10-05 Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer den Boer, R. B. Jones, K. I. Ash, S. van Boxel, G. I. Gillies, R. S. O'Donnell, T. Ruurda, J. P. Sgromo, B. Silva, M. A. Maynard, N. D. BJS Open Original Articles BACKGROUND: Risk assessment is relevant to predict postoperative outcomes in patients with gastro‐oesophageal cancer. This cohort study aimed to assess body composition changes during neoadjuvant chemotherapy and investigate their association with postoperative complications. METHODS: Consecutive patients with gastro‐oesophageal cancer undergoing neoadjuvant chemotherapy and surgery with curative intent between 2016 and 2019 were identified from a specific database and included in the study. CT images before and after neoadjuvant chemotherapy were used to assess the skeletal muscle index, sarcopenia, and subcutaneous and visceral fat index. RESULTS: In a cohort of 199 patients, the mean skeletal muscle index decreased during neoadjuvant therapy (from 51·187 to 49·19 cm(2)/m(2); P < 0·001) and the rate of sarcopenia increased (from 42·2 to 54·3 per cent; P < 0·001). A skeletal muscle index decrease greater than 5 per cent was not associated with an increased risk of total postoperative complications (odds ratio 0·91, 95 per cent c.i. 0·52 to 1·59; P = 0·736) or severe complications (odds ratio 0·66, 0·29 to 1·53; P = 0·329). CONCLUSION: Skeletal muscle index decreased during neoadjuvant therapy but was not associated with postoperative complications. John Wiley & Sons, Ltd 2020-08-25 /pmc/articles/PMC7528528/ /pubmed/32841538 http://dx.doi.org/10.1002/bjs5.50331 Text en © 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of British Journal of Surgery Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles den Boer, R. B. Jones, K. I. Ash, S. van Boxel, G. I. Gillies, R. S. O'Donnell, T. Ruurda, J. P. Sgromo, B. Silva, M. A. Maynard, N. D. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title | Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title_full | Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title_fullStr | Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title_full_unstemmed | Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title_short | Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
title_sort | impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528528/ https://www.ncbi.nlm.nih.gov/pubmed/32841538 http://dx.doi.org/10.1002/bjs5.50331 |
work_keys_str_mv | AT denboerrb impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT joneski impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT ashs impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT vanboxelgi impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT gilliesrs impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT odonnellt impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT ruurdajp impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT sgromob impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT silvama impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer AT maynardnd impactonpostoperativecomplicationsofchangesinskeletalmusclemassduringneoadjuvantchemotherapyforgastrooesophagealcancer |